President Donald Trump has chosen Dr. Scott Gottlieb, a conservative health policy expert with deep ties to the pharmaceutical industry, to lead the U.S. Food and Drug Administration, the White House said on Friday.
If confirmed by the Senate, Gottlieb would be in charge of implementing Trump's plan to dramatically cut regulations governing food, drugs, cosmetics, dietary supplements and tobacco.
Gottlieb is well known on Capitol Hill, where he has testified multiple times on hot-button health issues, including complex drug pricing matters, and is viewed favorably by drug companies and pharmaceutical investors. He sits on the boards of several small drug and biotech companies and is an adviser to GlaxoSmithKline Plc.
"Thank God it's Gottlieb," Brian Skorney, an investment analyst at Robert W. Baird, wrote in a research note. "We view this as a favorable development for the sector." More here... PG: Gottlieb received the most votes (27%) in my survey. Strangely, Jim O'Neill received 0%! See the results here. I've heard that Many Former #FDA Employees Take the "Revolving Door" & End Up Working for #Pharma (here) and that #Pharma Nearly Decimates FDA's CDER Division by "Poaching" Employees (here), but I haven't heard of a case of the "double-dutch" or FDA-Pharma-FDA revolving door, where a former FDA employee is hired by pharma who then later becomes FDA commissioner.